JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1989) 123, 19-24    DOI: 10.1677/joe.0.1230019
© 1989 Society for Endocrinology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bailey, C. J.
Right arrow Articles by Buchanan, K. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bailey, C. J.
Right arrow Articles by Buchanan, K. D.

Effects of growth hormone-releasing hormone on the secretion of islet hormones and on glucose homeostasis in lean and genetically obese-diabetic (ob/ob) mice and normal rats

C. J. Bailey, L. C. Wilkes, P. R. Flatt, J. M. Conlon and K. D. Buchanan

The effect of synthetic human growth hormone-releasing hormone(1–40) (hGHRH-40) on the function of the endocrine pancreas and on glucose homeostasis in lean and genetically obese-diabetic (ob/ob) mice and normal rats has been examined. The addition of 1 µmol hGHRH-40/1 to incubated islets from normal lean mice increased insulin release by 90 and 37% at 5·6 and 16·7 mmol glucose/l respectively. Lower concentrations of hGHRH-40 did not affect insulin release. hGHRH-40 (1 µmol/l) increased pancreatic polypeptide release by 50% at 5·6 mmol glucose/l. A range of concentrations of hGHRH-40 (1 nmol/l–1 µmol/l) reduced glucagon release by 42–73% at 5·6 mmol glucose/l, and by 38–70% at 16·7 mmol glucose/l. Somatostatin release was increased (eightfold) by 1 µmol hGHRH-40/1 at 5·6 mmol glucose/l, but at 1 nmol hGHRH-40/l somatostatin release was reduced (by > 50%). At 16·7 mmol glucose/litre 0·01–1 µmol hGHRH-40/l increased somatostatin release (three- to fourfold), but 1 nmol hGHRH-40/l produced a reduction of 50%. In vivo, administration of hGHRH-40 (50 µg/kg body weight i.p.) to fasted lean and ob/ob mice did not alter basal plasma concentrations of glucose and insulin, or the glucose and insulin responses to a concomitant i.p. glucose challenge. Intravenous injection of hGHRH-40 (20 µg/kg body weight) to anaesthetized rats increased plasma concentrations of insulin in the hepatic portal vein. A lower dose of hGHRH-40 (0·2 µg/kg) was ineffective, and neither dose of hGHRH-40 altered plasma glucose. The results indicate that hGHRH-40 exerts dose-dependent effects on the secretion of islet hormones, but this does not appear to be sufficient to produce measurable effects on plasma glucose homeostasis.

Journal of Endocrinology (1989) 123, 19–24







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the Society for Endocrinology.